2025-524134-26-00RecruitingPhase 1
Effect of NBI-921355 on corticospinal excitability in healthy participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 4 May 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 16 Mar 2026
- Start date
- 8 May 2026
- Lead sponsor
- Neurocrine Biosciences Inc.
- EU CT number
- 2025-524134-26-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 24
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy adults to study how the study drug NBI-921355 affects the excitability of the nerve pathway between the brain and the spinal cord.
- Age
- 18 Years to 64 Years
- Sex
- All sexes can join.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Human Drug Research | Leiden | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.